Posted by Michael Wonder on 11 Jul 2018
Supply of 100 UK medicines to be disrupted, warns EMA
11 July 2018 - EMA said work to license them after Brexit has not been done.
The supply of more than 100 medicines manufactured solely in the UK is at risk of disruption post-Brexit because necessary work to ensure they can be licensed and released for sale in mainland Europe has not yet been carried out.
The assessment has come from the EMA, the regulator, following a survey of action taken by pharmaceutical companies to safeguard supplies of almost 700 products whose marketing authorisations were granted in the UK.
